February: New Drug Approvals by the NMPA - January 2024

• Imported drugs:
•  □　Galcanezumab injection (Brand name: Emgality) marketed by Eli Lilly Nederland B.V.
• □　Itraconazole oral solution marketed by Hwang's Pharmaceutical Co., Ltd.
• □　Lecanemab injection (Brand name: Leqembi) marketed by Eisai Inc.
• □　Recombinant Human Papillomavirus 9-Valent Vaccine (Brand name: GARDASIL 9) marketed by: Merck Sharp & Dohme LLC - Newly approved as two doses in women aged 9-14 years old.
• □　Rimegepant sulfate orally disintegrating tablets (Brand name: NURTEC) marketed by Pfizer Inc.
• □　Semaglutide tablet (Brand name: Rybelsus) marketed by Novo Nordisk A/S

 

• Domestic drugs:
• □　Amlodipine besilate for suspension marketed by ApicHope Pharmaceutical Co., Ltd
• □　Diazoxide oral suspension marketed by Yifan Pharmaceutical Co., Ltd.
• □　Ebastine oral solution marketed by Hunan Pudao Pharmaceutical Technology, subsidiary of Jiudian Pharmaceutical
• □　Eltrombopag olamine tablets marketed by: Kelun Industry Group / Qilu Pharmaceutical / CTTQ Pharma / Jiangsu Aosaikang Pharmaceutical Co., Ltd.
• □　Ganagliflozin proline tablets (Brand name: 惠优静 (Hui You Jing)) marketed by Huisheng Pharm
• □　Iruplinalkib tablets (Brand name: 启欣可 (Qi Xin Ke)) marketed by Qilu Pharmaceutical - Newly approved for the treatment of locally advanced or metastatic ALK-positive NSCLC.
• □　Itraconazole oral solution marketed by Hefei Chengzhi Biopharmaceutical Co., Ltd.
• □　Sevelamer carbonate for suspension marketed by Hangzhou Anprime Biopharm Co., Ltd
• □　Tegileridine fumarate injection (Brand name: 艾苏特 (Ai Su Te)) marketed by: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

 

• (Source: BaiPharm)